Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

CELZ-201-DDT · CELZ-201

Other · developed by Creative Medical Technology Holdings

Phase 1/2 Most advanced trial
CELZ Developer
1 Registered trials

What is CELZ-201-DDT?

CELZ-201-DDT is an investigational drug studied in Chronic Low-back Pain, Degenerative Disc Disease.

At a glance

Also known as
CELZ-201
Drug type
Other
Therapy area
Musculoskeletal
Developer
Creative Medical Technology Holdings Inc (CELZ)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06053242 Phase 1/2 Chronic Low-back Pain Active not recruiting CELZ

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Low-back PainDegenerative Disc Disease

More from Creative Medical Technology Holdings

CELZ-201 Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the CELZ page.

Follow CELZ, the company behind CELZ-201-DDT

See CELZ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CELZ catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.